It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Ischemia-induced neuronal death leads to serious lifelong neurological deficits in ischemic stroke patients. Histone deacetylase 6 (HDAC6) is a promising target for neuroprotection in many neurological disorders, including ischemic stroke. However, the mechanism by which HDAC6 inhibition protects neurons after ischemic stroke remains unclear. Here, we discovered that genetic ablation or pharmacological inhibition of HDAC6 reduced brain injury after ischemic stroke by increasing macrophage migration inhibitory factor (MIF) acetylation. Mass spectrum analysis and biochemical results revealed that HDAC6 inhibitor or aspirin treatment promoted MIF acetylation on the K78 residue. MIF K78 acetylation suppressed the interaction between MIF and AIF, which impaired MIF translocation to the nucleus in ischemic cortical neurons. Moreover, neuronal DNA fragmentation and neuronal death were impaired in the cortex after ischemia in MIF K78Q mutant mice. Our results indicate that the neuroprotective effect of HDAC6 inhibition and aspirin treatment results from MIF K78 acetylation; thus, MIF K78 acetylation may be a therapeutic target for ischemic stroke and other neurological diseases.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 the Affiliated Hospital of Xuzhou Medical University, Xuzhou Medical University, Institute of Stroke Research and Department of Neurology, Xuzhou, China (GRID:grid.417303.2) (ISNI:0000 0000 9927 0537)
2 the Affiliated Hospital of Xuzhou Medical University, Xuzhou Medical University, Institute of Stroke Research and Department of Neurology, Xuzhou, China (GRID:grid.417303.2) (ISNI:0000 0000 9927 0537); ShanghaiTech University, Shanghai, China (GRID:grid.440637.2) (ISNI:0000 0004 4657 8879); Affiliated municipal Hospital of Xuzhou Medical University; Xuzhou Medical University, Department of Neurology, Xuzhou, China (GRID:grid.417303.2) (ISNI:0000 0000 9927 0537)
3 ShanghaiTech University, Shanghai, China (GRID:grid.440637.2) (ISNI:0000 0004 4657 8879); University of Chinese Academy of Sciences, Beijing, China (GRID:grid.410726.6) (ISNI:0000 0004 1797 8419)
4 ShanghaiTech University, Shanghai, China (GRID:grid.440637.2) (ISNI:0000 0004 4657 8879)
5 Xuzhou Medical University, Cancer Institute, Xuzhou, China (GRID:grid.417303.2) (ISNI:0000 0000 9927 0537)